Mink TherapeuticsINKT
13F holders, Q2 2025 (June 30)19holders +3
4new positions
1sold out
$7.44avg. 13F price*
At the end of Q2 2025, 19 institutions reported holding Mink Therapeutics Inc. (INKT) in their 13F filings, up 3 from Q1 2025. 4 opened new positions and 1 sold out. The largest holders were Vanguard Group Inc. ($178K), Longbow Finance SA ($123K) and Geode Capital Management, LLC ($86K).
- Company
- Mink Therapeutics Inc.
- CUSIP
- 603693201
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $127K |
| Exits | 1 | $1K |
All 13F filers, Q1 2025 → Q2 2025: 17,473 shares bought and 1,856 shares sold, net +15,617 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Vanguard Group Inc. | 0.00% | No change | 23,744 | $178K |
| Longbow Finance SA | 0.01% | New | 16,667 | $123K |
| Geode Capital Management, LLC | 0.00% | Add +2.1% | 11,492 | $86K |
| BlackRock, Inc. | 0.00% | Reduce -15.5% | 7,421 | $55K |
| Wells Fargo & Company | 0.00% | Add +0.1% | 849 | $6K |
| Bank of America Corp. | 0.00% | Reduce -25.0% | 568 | $4K |
| Total Investment Management Inc. | 0.00% | New | 500 | $4K |
| UBS Group AG | 0.00% | No change | 284 | $2K |
| Covestor Ltd | 0.00% | Add +26.0% | 131 | $1K |
| Osaic Holdings, Inc. | 0.00% | Reduce -49.6% | 120 | $883 |
| Raymond James Financial Inc. | 0.00% | New | 32 | $236 |
| BNP Paribas Financial Markets | 0.00% | Add +13.0% | 26 | $192 |
| Morgan Stanley | 0.00% | Reduce -8.3% | 22 | $163 |
| Northwestern Mutual Wealth Management Co. | 0.00% | Add +5.6% | 19 | $140 |
| Game Plan Financial Advisors, LLC | 0.00% | No change | 16 | $118 |
| Clearstead Advisors, LLC | 0.00% | No change | 14 | $104 |
| JPMorgan Chase & Co. | 0.00% | Reduce -60.0% | 12 | $89 |
| Key Financial Inc | 0.00% | New | 4 | $30 |
| Jones Financial Companies LLLP | 0.00% | No change | 1 | $7 |
"% of holder's portfolio" is INKT's weight in each manager's 13F, not the share of Mink Therapeutics Inc. the manager owns.